fenofibrate has been researched along with Chronic Kidney Diseases in 16 studies
Pharmavit: a polyvitamin product, comprising vitamins A, D2, B1, B2, B6, C, E, nicotinamide, & calcium pantothene; may be a promising agent for application to human populations exposed to carcinogenic and genetic hazards of ionizing radiation; RN from CHEMLINE
| Excerpt | Relevance | Reference |
|---|---|---|
| "This multicenter, randomized study evaluated the short-term efficacy and safety profile of fenofibric acid (FA) + rosuvastatin (R) combination therapy for improving lipid parameters in patients with stage 3 CKD and mixed dyslipidemia." | 5.17 | A randomized, double-blind study of fenofibric acid plus rosuvastatin compared with rosuvastatin alone in stage 3 chronic kidney disease. ( Burns, KM; Carlson, DM; Kelly, MT; Lele, A; Setze, CM; Stolzenbach, JC; Weinstein, DL; Williams, LA, 2013) |
| "For patients with type 2 diabetes at high CV risk but no CKD, fenofibrate therapy added to statin reduced the CV mortality and the rate of fatal and non-fatal CHF." | 2.84 | Effects of High Density Lipoprotein Raising Therapies on Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus, with or without Renal Impairment: The Action to Control Cardiovascular Risk in Diabetes Study. ( Applegate, WB; Cushman, W; Doumas, M; Lovato, L; Mottle, A; Nylen, E; Papademetriou, V; Punthakee, Z; Tsioufis, C, 2017) |
| " We suggest that Pema may be an effective and safe treatment for hypertriglyceridemia in CKD patients." | 1.91 | Efficacy and safety of pemafibrate in patients with chronic kidney disease: A retrospective study. ( Fukuda, H; Iwasaki, M; Koshida, T; Matsuzaki, K; Saito, M; Suzuki, H; Suzuki, Y; Takahara, H; Umezawa, Y, 2023) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (12.50) | 29.6817 |
| 2010's | 9 (56.25) | 24.3611 |
| 2020's | 5 (31.25) | 2.80 |
| Authors | Studies |
|---|---|
| Hernandez-Arroyo, CF | 1 |
| Kanduri, SR | 1 |
| Justiniano, R | 1 |
| Martinez-Pitre, PJ | 1 |
| Velez, JCQ | 1 |
| Iwasaki, M | 1 |
| Suzuki, H | 1 |
| Umezawa, Y | 1 |
| Koshida, T | 1 |
| Saito, M | 1 |
| Fukuda, H | 1 |
| Takahara, H | 1 |
| Matsuzaki, K | 1 |
| Suzuki, Y | 1 |
| Horinouchi, Y | 1 |
| Murashima, Y | 1 |
| Yamada, Y | 1 |
| Yoshioka, S | 1 |
| Fukushima, K | 1 |
| Kure, T | 1 |
| Sasaki, N | 1 |
| Imanishi, M | 1 |
| Fujino, H | 1 |
| Tsuchiya, K | 1 |
| Shinomiya, K | 1 |
| Ikeda, Y | 1 |
| Yen, CL | 1 |
| Fan, PC | 1 |
| Lin, MS | 1 |
| Lee, CC | 1 |
| Tu, KH | 1 |
| Chen, CY | 1 |
| Hsiao, CC | 1 |
| Hsu, HH | 1 |
| Tian, YC | 1 |
| Chang, CH | 1 |
| Streja, E | 1 |
| Streja, DA | 1 |
| Soohoo, M | 1 |
| Kleine, CE | 1 |
| Hsiung, JT | 1 |
| Park, C | 1 |
| Moradi, H | 1 |
| Maas, R | 1 |
| Mieth, M | 1 |
| Titze, SI | 1 |
| Hübner, S | 1 |
| Fromm, MF | 1 |
| Kielstein, JT | 1 |
| Schmid, M | 1 |
| Köttgen, A | 1 |
| Kronenberg, F | 1 |
| Krane, V | 1 |
| Hausknecht, B | 1 |
| Eckardt, KU | 1 |
| Schneider, MP | 1 |
| Katsiki, N | 1 |
| Mikhailidis, DP | 1 |
| Banach, M | 1 |
| Weinstein, DL | 1 |
| Williams, LA | 1 |
| Carlson, DM | 1 |
| Kelly, MT | 1 |
| Burns, KM | 1 |
| Setze, CM | 1 |
| Lele, A | 1 |
| Stolzenbach, JC | 1 |
| Saito, T | 1 |
| Matsunaga, A | 1 |
| Ito, K | 1 |
| Nakashima, H | 1 |
| Márk, L | 1 |
| Dani, G | 1 |
| Papademetriou, V | 1 |
| Lovato, L | 1 |
| Tsioufis, C | 1 |
| Cushman, W | 1 |
| Applegate, WB | 1 |
| Mottle, A | 1 |
| Punthakee, Z | 1 |
| Nylen, E | 1 |
| Doumas, M | 1 |
| Kaysen, GA | 1 |
| Sousa, AA | 1 |
| Kronit, HS | 1 |
| Neves, Fde A | 1 |
| Amato, AA | 1 |
| Tanaka, Y | 1 |
| Kume, S | 1 |
| Araki, S | 1 |
| Isshiki, K | 1 |
| Chin-Kanasaki, M | 1 |
| Sakaguchi, M | 1 |
| Sugimoto, T | 1 |
| Koya, D | 1 |
| Haneda, M | 1 |
| Kashiwagi, A | 1 |
| Maegawa, H | 1 |
| Uzu, T | 1 |
| Lewis, D | 1 |
| Wanner, C | 1 |
| Paul, S | 1 |
| Mohan, V | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A 30-Week, Multicenter, Randomized, Double-Blind, Parallel-Group Study of the Combination of ABT-335 and Rosuvastatin Compared to Rosuvastatin Monotherapy in Dyslipidemic Subjects With Stage 3 Chronic Kidney Disease[NCT00680017] | Phase 3 | 280 participants (Actual) | Interventional | 2008-06-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
High-density lipoprotein cholesterol (HDL-C) was measured in milligrams/deciliter (mg/dL). (NCT00680017)
Timeframe: Baseline to 8 weeks
| Intervention | percent change (Least Squares Mean) |
|---|---|
| ABT-335 Plus Rosuvastatin | 16.9 |
| Rosuvastatin | 7.8 |
Triglycerides were measured in milligrams/deciliter. (NCT00680017)
Timeframe: Baseline to 8 weeks
| Intervention | percent change (Median) |
|---|---|
| ABT-335 Plus Rosuvastatin | -38.0 |
| Rosuvastatin | -22.4 |
4 reviews available for fenofibrate and Chronic Kidney Diseases
| Article | Year |
|---|---|
Precision Medicine and Personalized Management of Lipoprotein and Lipid Disorders in Chronic and End-Stage Kidney Disease.
Topics: Anticholesteremic Agents; Cardiovascular Diseases; Dyslipidemias; Ezetimibe; Fenofibrate; Humans; Hy | 2018 |
Lipid-lowering agents for concurrent cardiovascular and chronic kidney disease.
Topics: Cardiovascular Diseases; Cholesterol, LDL; Ezetimibe; Fatty Acids, Omega-3; Fenofibrate; Humans; Hyd | 2019 |
Topics in lipoprotein glomerulopathy: an overview.
Topics: Apolipoprotein E2; Apolipoproteins E; Fenofibrate; Founder Effect; Humans; Hypertriglyceridemia; Kid | 2014 |
[Diabetic dyslipidaemia and the atherosclerosis].
Topics: Apolipoprotein A-V; Apolipoproteins A; Apolipoproteins C; Atherosclerosis; Cardiovascular Diseases; | 2016 |
2 trials available for fenofibrate and Chronic Kidney Diseases
| Article | Year |
|---|---|
A randomized, double-blind study of fenofibric acid plus rosuvastatin compared with rosuvastatin alone in stage 3 chronic kidney disease.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Cardiovascular Diseases; Chole | 2013 |
Effects of High Density Lipoprotein Raising Therapies on Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus, with or without Renal Impairment: The Action to Control Cardiovascular Risk in Diabetes Study.
Topics: Aged; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Fenofib | 2017 |
10 other studies available for fenofibrate and Chronic Kidney Diseases
| Article | Year |
|---|---|
Improvement in Kidney Function after Discontinuation of Fenofibrate in Outpatient Nephrology Consultation for Chronic Kidney Disease.
Topics: Creatinine; Diabetes Mellitus, Type 2; Female; Fenofibrate; Glomerular Filtration Rate; Humans; Kidn | 2022 |
Efficacy and safety of pemafibrate in patients with chronic kidney disease: A retrospective study.
Topics: Bezafibrate; Drug Substitution; Fenofibrate; Humans; Hypertriglyceridemia; Renal Insufficiency; Rena | 2023 |
Pemafibrate inhibited renal dysfunction and fibrosis in a mouse model of adenine-induced chronic kidney disease.
Topics: Animals; Creatinine; Fenofibrate; Fibrosis; Kidney; Mice; PPAR alpha; Renal Insufficiency, Chronic; | 2023 |
Fenofibrate Delays the Need for Dialysis and Reduces Cardiovascular Risk Among Patients With Advanced CKD.
Topics: Adult; Aged; Cardiovascular Diseases; Cohort Studies; Disease Progression; Female; Fenofibrate; Hear | 2021 |
Drugs linked to plasma homoarginine in chronic kidney disease patients-a cross-sectional analysis of the German Chronic Kidney Disease cohort.
Topics: Adolescent; Adult; Aged; Cohort Studies; Cross-Sectional Studies; Disease Progression; Female; Fenof | 2020 |
Lipid-Lowering Therapy in CKD: Should We Use It and in Which Patients.
Topics: Cardiovascular Diseases; Fenofibrate; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoli | 2017 |
Fenofibrate-induced rhabdomyolysis in a patient with chronic kidney disease: an unusual presenting feature of hypothyroidism.
Topics: Fenofibrate; Humans; Hypertriglyceridemia; Hypolipidemic Agents; Hypothyroidism; Male; Middle Aged; | 2009 |
Fenofibrate, a PPARα agonist, has renoprotective effects in mice by enhancing renal lipolysis.
Topics: Animals; Anti-Inflammatory Agents; Base Sequence; Cells, Cultured; Chemokine CCL2; Dietary Fats; Dis | 2011 |
Diabetes: Should we use fibrates in patients with diabetes and mild CKD?
Topics: Diabetes Mellitus, Type 2; Diabetic Nephropathies; Dyslipidemias; Fenofibrate; Humans; Hypolipidemic | 2012 |
Fenofibrate can increase serum creatinine levels in renal insufficiency.
Topics: Contraindications; Creatinine; Fenofibrate; Humans; Hypertriglyceridemia; Hypolipidemic Agents; Rena | 2006 |